Structure Therapeutics stock rating reiterated by Cantor Fitzgerald

Structure Therapeutics (NASDAQ:GPCR) has received strong analyst backing, with Cantor Fitzgerald reiterating an Overweight rating and a $65.00 price target, citing the stock's undervaluation and the significant potential of its oral GLP-1 agonist, aleniglipron. Analysts highlight aleniglipron's structural similarities to Eli Lilly's orforglipron, which achieved approximately 11% placebo-adjusted weight loss, and note the recent approval for higher dosing in GPCR's ongoing Phase 2B trials, indicating favorable tolerability. With key Phase 2B obesity trial results anticipated by the end of 2025, the company is positioned as a promising player in the oral drug market, driving analyst price targets ranging from $37 to $120.

Analysis

Structure Therapeutics (NASDAQ:GPCR) is receiving strong bullish support from sell-side analysts, underpinned by the potential of its oral GLP-1 agonist, aleniglipron. Cantor Fitzgerald reiterated an Overweight rating with a $65.00 price target, highlighting a significant valuation gap compared to the current price of $21.79. The core of the investment thesis rests on the direct structural and chemical similarities between aleniglipron and Eli Lilly's orforglipron, which achieved an approximate 11% placebo-adjusted weight loss at 36 weeks, setting a positive performance benchmark. A key de-risking event has occurred, as the company's data monitoring committee approved dose escalation up to 240 mg in ongoing Phase 2B trials. Analysts interpret this as a favorable safety signal, suggesting an absence of liver toxicity concerns at higher exposures. While there is a strong consensus on the stock's potential, with multiple firms holding Buy or Outperform ratings, the wide dispersion of price targets, ranging from $37 to $120, reflects varying assumptions about clinical success and market penetration. The next major catalyst is the release of Phase 2B obesity trial data, anticipated by the end of 2025.

Key Decisions for Investors

• Given the substantial upside implied by analyst price targets and positive early safety signals, investors with a high-risk tolerance for clinical-stage biotechs may view the current price as a compelling entry point ahead of key clinical data.
• The primary value driver for GPCR is the Phase 2B obesity trial; investors should closely monitor for any updates on trial progress, as the results expected by year-end 2025 will be the most significant determinant of the stock's future trajectory.
• Investors should treat developments related to Eli Lilly's orforglipron as a direct read-through for Structure Therapeutics, as its clinical performance and safety profile are being used as a primary benchmark for aleniglipron's potential.
• The wide range in analyst price targets underscores the inherent valuation uncertainty and high-risk, high-reward nature of the asset, warranting caution and position sizing appropriate for a volatile, event-driven biotechnology stock.